Eli Lilly (LLY) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $1.18T | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | David A. Ricks |
| IPO Date | 1972-06-01 | CAGR | 7.77% |
| Employees | 50,000 | Website | www.lilly.com |
| Div. Yield | 0.37% | Payout Ratio | 22% |
| Buy Back Yield | 0.38% | Total Yield | 0.75% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $1187.28B | P/E | 39.85 | Forward P/E | 26.52 | PEG | 1.6 |
| P/S | 20.65 | P/B | 46.02 | P/CF | 55.49 | P/FCF | 82.05 |
| Sales | $79.67B | Sales 1Y | 49.58% | Sales 3Y | 169.91% | Sales 5Y | 198.08% |
| EPS | $31.49 | EPS 1Y | 94.77% | EPS 3Y | 330.01% | EPS 5Y | 364.9% |
| Sales QoQ | 16.04% | EPS QoQ | -3.87% | Sales QoQ Avg | 10.35% | EPS QoQ Avg | 6.41% |
| Gross Margin | 84.01% | Operating Margin | 43.92% | Profit Margin | 33.53% | ROCE | 37.01% |
| ROA | 19% | ROE | 93% | Altman Z Score | 8.3 | Piotroski Score | 8 |
| Current Ratio | 1.35 | Quick Ratio | 1 | Cash Ratio | 0.19 | Op. CF Ratio | 0.22 |
| Debt/Equity | 1.62 | Debt/Assets | 0.39 | Lt Debt/Equity | 1.41 | Lt Debt/Cap. | 0.59 |
| Intrst Cov. | 35.72 | Inventory Turnover | 0.76 | Asset Turnover | 0.56 | Receivables Turnover | 3.39 |
| Enterprise Value | $1187.28B | P/E Ratio | 39.85 |
| Forward P/E | 26.52 | PEG Ratio | 1.6 |
| P/S Ratio | 20.65 | P/B Ratio | 46.02 |
| P/CF Ratio | 55.49 | P/FCF Ratio | 82.05 |
| EPS | $31.49 | EPS Growth 1Y | 94.77% |
| EPS Growth 3Y | 330.01% | EPS Growth 5Y | 364.9% |
| Revenue Growth 1Y | 49.58% | Gross Margin | 0.84% |
| Operating Margin | 0.44% | Profit Margin | 0.34% |
| ROE | 0.93% | ROA | 0.19% |
| ROCE | 0.37% | Current Ratio | 1.35 |
| Quick Ratio | 1 | Cash Ratio | 0.19 |
| Debt/Equity | 1.62 | Interest Coverage | 35.72 |
| Altman Z Score | 8.3 | Piotroski Score | 8 |
Eli Lilly (LLY) valuation & financials
Eli Lilly (LLY) has a market capitalization of $1.18T and trades at a price-to-earnings ratio of 39.9. It operates in the Healthcare sector (Drug Manufacturers - General).
Eli Lilly's revenue grew +49.6% over the last year.
Eli Lilly's next earnings report is scheduled for October 29, 2026 before market open; analysts estimate EPS of $9.85. Check the earnings calendar to see all companies reporting this week.
Eli Lilly (LLY) — frequently asked questions
When does Eli Lilly (LLY) report earnings next?
Eli Lilly is expected to report earnings on October 29, 2026 before market open. Analysts estimate EPS of $9.85.
What is Eli Lilly's market cap?
Eli Lilly (LLY) has a market capitalization of $1.18T.
What is LLY's P/E ratio?
Eli Lilly trades at a price-to-earnings ratio of 39.9, with trailing twelve-month EPS of $31.49.
How fast is Eli Lilly growing?
Eli Lilly's revenue grew +49.6% over the last year.
Compare with other Healthcare companies: Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW) · Novartis (NVS)